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Abstract (150 words) 
 
In primary Sjögren's syndrome (pSS), clinical features in SS can be divided into two facets: the 
patient perceived manifestations such as dryness, pain and fatigue, and the systemic 
manifestations.  
In the past decades, with efforts made by an international collaboration,  consensual clinical 
indexes were developed for assessing both facets: one patient reported outcome, the EULAR 
Sjögren's Syndrome Patients Reported Index (ESSPRI), and one activity index for systemic 
manifestations, the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). In addition, 
objective measures were developed to quantify the importance and consequence of ocular 
and oral dryness, few being specific of pSS. Work is ongoing to develop indexes combining all 
these approaches.   
Recent changes in the way to assess pSS patients, and emergence of new targeted therapies, 
have put a great input in the design of clinical trials in pSS, and led for the first time to a 
positive randomised clinical trial.   
Key messages (15 words each) 
- Clinical features in primary Sjögren's syndrome (pSS), in SS can be divided in patient 
symptoms (dryness, pain and fatigue) and systemic manifestations.  
- Clinical evaluation of pSS has evolved through the development of tools for the 2 
facets 
- In the most recent pSS trials, evaluation of systemic manifestations as primary 
outcome led for the first time to encouraging results 




Primary Sjögren’s syndrome (pSS) is a systemic disorder primarily characterized by 
lymphocytic infiltration of exocrine glands, resulting in functional impairment of salivary and 
lachrymal glands. The inflammatory process, however, extends beyond the exocrine glands 
and can potentially affect any organ. Therefore, along with dryness features, systemic 
manifestations such as synovitis, vasculitis, and skin, lung, renal and neurological involvement 
may occur. Also, chronic B cell activation, which is a hallmark of the disease, is responsible for 
an increased risk of lymphoma [1].  
As a result, clinical features can be divided into two facets: (i) benign but disabling 
patients’ symptoms such as dryness, pain and fatigue that affect almost all patients; and (ii) 
potentially severe systemic manifestations that affect 20%─ 40% of patients. During the past 
decade, with the arrival of targeted therapies, outcome assessment has largely progressed 
thanks to the effort of the international collaboration set up by the EULAR Sjögren’s task 
force. Thus, two outcome measures have been developed for evaluation of both disease 
facets: the EULAR SS Patient Reported Index (ESSPRI) for patients’ symptoms [2] and the 
EULAR SS Disease Activity Index (ESSDAI) for systemic features [3]. As a consequence, 
evidence-based therapy for Sjögren’s syndrome has evolved, from addressing principally sicca 
features and Patient Reported Outcomes (PROs) [4] [5-7] [8, 9] to the use of systemic disease 
activity measures, ie ESSDAI as the primary outcome measure for  almost all recent and 
ongoing clinical trials. The purpose of this article is to address the evidence-based evaluations 
that have emerged in pSS. 
 
1. Systemic Disease Activity Measures, through a consensual scoring: the ESSDAI 
For the evaluation of systemic activity, the SS disease activity index (SSDAI) [10] was 
the first activity index proposed for SS. It had the benefit of simplicity, but lacked 
exhaustiveness and missed some of the rare but severe manifestations of pSS [11]. By 
contrast, the Sjögren’s Systemic Clinical Activity Index (SCAI)[12] developed at the same time 
was much more exhaustive, but was complex to rate such that it was challenging to use it in 
clinical practice. These tools, however, served as the basis for developing the ESSDAI that 
offers the advantage of being exhaustive but also simple to use.  
The ESSDAI is a disease activity index that was generated in 2009. The score was 
developed by consensus of a large group of worldwide experts from European and North 
American countries [12, 13] using patients’ data. The ESSDAI (table 1) is a systemic disease 
activity index and includes 12 domains (i.e. organ systems: cutaneous, respiratory, renal, 
articular, muscular, PNS, CNS, haematological, glandular, constitutional, lymphadenopathy, 
biological). Before rating each domain, physician is asked to rate only manifestations related 
to the disease and to avoid rating long lasting clinical features and exclude rating of damage. 
The final score sums all domain scores and falls between 0 and, theoretically, 123, with 0 
indicating no disease activity. Disease activity levels have been determined as follows: low 
activity (ESSDAI < 5), moderate (ESSDAI: 5 to 13) and high activity (ESSDAI ≥14) [14]. Also, 
minimal clinically important improvement (MCII) has been defined as an improvement of the 
ESSDAI score by at least 3 points. 
To date, the ESSDAI has been used and evaluated in many studies and has become the 
consensus tool to evaluate systemic disease activity. The good sensitivity to change of ESSDAI 
has been confirmed in independent cohorts of patients treated by rituximab in clinical trials 
[15, 16], even though the randomized controlled trials failed to demonstrate treatment 
efficacy when ESSDAI was not used a primary outcome [17, 18]. Of note, ESSPRI and ESSDAI 
have been found to be poorly correlated in different studies [19-21], which suggests that 
patients’ symptoms and systemic complications are two different components, that should 
both be evaluated, but separately. With the increasing use of ESSDAI, it became clear that a 
more extensive explanation of the way to use it would be helpful for clinical trials. Thus, a 
user guide has been published to help and clarify the rating of each domain [22]. These tools 
are now used to define entry criteria and the primary outcome of most of the recent and 
ongoing trials and a recent trial using ESSDAI as primary outcome demonstrated efficacy of 
an anti-CD40 monoclonal antibody [23]. 
 
2. Patient Reported Outcome Measures & Glandular Disease Activity Indices 
Dryness (Sicca), particularly of eyes and mouth, are the key symptoms of Sjogren’s syndrome 
and are present in 95% of patients with pSS [24]. Fatigue is also a major problem reported by 
65-70% of patients and is also linked to reduced health-related quality of life (HRQoL) in pSS 
[25]. Arthralgia/myalgia under the broader term of ‘limb pain’ is the third commonly 
recognized component of the Sjogren’s ‘symptom triad’ of ‘dryness’, ‘fatigue’ and ‘pain’. 
The distinction between ‘fatigue and pain’ on the one hand and ‘dryness’ on the other is that 
the formers are purely symptomatic, at least in this context, ie there is no objective measure 
of fatiguability, or pain threshold currently used in the assessment of pain and fatigue in pSS. 
These are rather measured by visual analogue scales (VAS) or by a discrete numeric Likert 
scale (eg 0-10), or by questionnaire. Conversely, whilst improvement in symptomatic dryness 
is also a critical goal of therapy in pSS this is generally linked to a co-assessment of objective 
measures of glandular function such as tear production, ocular surface staining (reflecting a 
lack of tear production) and salivary flow. This applies to the assessment of both salivary 
stimulants such as Pilocarpine and potential disease-modifying therapies to suppress 
glandular inflammation. 
We will therefore consider these separately as well as considering how they integrate 
together in composite measures and how ‘global’ or HRQoL measures fit into the overall 
picture.  
2.1. Oral Features 
One of the main complaints of SS is dry mouth. The definition of dry mouth includes 
xerostomia, subjective sensation of dryness, and hyposalivation (ie. quantitative decrease of 
saliva production due to salivary gland impairment). Also, xerostomia should lead to further 
explorations, as it could result from other conditions, mainly medication side effects [26]. 
Interestingly, in general as in pSS, xerostomia does not necessarily correlate with measures 
of hyposalivation [27]. In pSS, changes in saliva composition have been described, such as 
increased mucin glycosylation that could explain the dry mouth sensation [28]. Today, no 
tools are available to assess saliva qualitative changes. The alterations of saliva flow and 
composition affect the equilibrium of the mouth, leading to a higher rate of oral disabilities, 
such as dental caries, periodontal disease, candidiasis, taste disturbances and a burning 
mouth sensation [29], decreased health-related quality of life [30] and anxiety, and stress and 
depression [31]. Clinical evaluation of dental and periondontal diseases should not be 
neglected and patients should be referred to oral medicine specialists.  
From the patient point of view, xerostomia assessment could be performed using different 
tools [32] such as the Xerostomia-Related Quality of Life Scale (XeQOLS) [33]) or the 
Xerostomia Inventory [34]. None of these questionnaires have been designed specifically for 
the assessment of xerostomia in pSS patients, and few data are available in this population. 
The XeQOLS was initially designed for patients with hyposalivation complicating salivary gland 
irradiation in orofacial cancer. It includes 15 items exploring 4 domains (physical functioning, 
pain/discomfort, personal/psychological functioning and social functioning) [33]. The 
Xerostomia Inventory has been set up in ageing people (≥ 65 years old). It includes 11 items 
that cover both experiential and behavioural aspects of dryness and 4 items are dedicated for 
extra-oral tissue dryness assessment (eyes, nose, face, lips) [34]. Both tools are easy to use in 
daily practice for physicians and dentists. 
For assessment of oral health-related quality of life, the Oral Health Impact Profile OHIP-14 
[30] is one of the most  widely used questionnaires in dental research studies in various 
populations (elderly, children…) and conditions (tooth decay, periodontal diseases, 
prosthesis…). OHIP-14 is a shorter version of the OHIP-49 previously developed [35]. OHIP-14 
is patient-centred and aims to assess seven dimensions of impacts of oral conditions on 
people’s oral quality of life, including functional limitation, physical pain, psychological 
discomfort, physical disability, psychological disability, social disability and handicap on the 
last past year. In patients with pSS, it has been found that salivary flow rate correlated 
significantly with OHIP-14 ratings [36, 37]. 
In daily practice, dry mouth can be easily screened for using the two questions of the 2002 
American-European consensus classification criteria for SS: (1) the presence of dry mouth 
more than 3 months and (2) the need to drink liquids to aid in swallowing dry [38]. Then, the 
objective assessment of hyposalivation should be performed with a measure of the 
Unstimulated Whole Salivary Flow (UWSF), considered as abnormal if ≤ 0.1 mL/min [39]. This 
was also incorporated into the 2016 ACR-EULAR classification criteria  [40]. UWSF is 
physiologically mainly produced by the submandibular glands at a 0.3-0.4 mL/min rate [32]. 
UWSF appears to be more sensitive for the diagnosis of SS because it is more frequently 
abnormal than the stimulated WSF in patients with pSS [41]. Recently, the Clinical Oral 
Dryness Score has been proposed as an alternative to USWF measurement which is very rarely 
performed in daily practice. This score includes 10 items to assess oral dryness by simple tests 
such as placing a mirror onto the oral mucosa and  tongue to assess ‘stickiness’ or 
observations such as the glassy appearance of the oral mucosa, especially the palate, or the 
presence of frothy saliva. However, the score of each items was not correlated with the value 
of hyposalivation (severe, moderate or none hyposalivation) [42]. Once SS is diagnosed, the 
assessment of dryness symptoms of patients with SS, both of mouth and eyes, are recorded 
by specific PROs, such as the Sicca Symptom Inventory (SSI) [43] but also the ESSPRI, also 
integrating the other main patients features, ie pain and fatigue [2] into a single measure. 
 
Some clinical data has suggested that the salivary flow rate and symptoms may transiently 
improve after rituximab , particularily in patients having a residual salivary flow before 
treatment and/or recently diagnosed pSS (less than 5 years) [44] [45, 46]. 
 
2.2. Ocular Indices 
Inflammation of the lacrimal glands with reduced or absent tear production leading to ocular 
sicca (dryness) symptoms was embedded within the classification criteria for pSS [38]. The 
presence of dry eyes for more than three months, foreign-body sensation, use of tear 
substitutes more than three times daily in association with signs of ocular surface staining 
representing areas of devitalised or absent epithelial cells are symptoms that should 
encourage physician to perform diagnostic procedures for SS.  In 2017, the Tear Film and 
Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) revised their definition of dry eye 
to a multifactorial disease of the ocular surface characterised by a loss of homeostasis of the 
tear film, and accompanied by ocular symptoms, in which tear film instability and 
hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities 
play aetiological roles [47]. This differs from the 2007 definition [48] by recognising the 
significant role of inflammation and hyperosmolarity within the dry eye pathway and the 
presence of corneal neuropathic pain in the absence of clinical signs of dry eye [49]; a 
phenomenon previously known as ‘pain without stain’ [50]. The diagnostic methodology 
report from TFOS DEWS II undertook a detailed meta-analysis of the methods available for 
scoring patients perception of dry eye disease and quantifying clinical aspects of disease 
activity [51], and goes a considerable way to simplifying quantification of disease for diagnosis 
and monitoring of management strategies (Figure 1), but is not widely used in pSS.  
Challenged by the fact that the patients’ symptoms and clinical signs of dry eye do not 
represent a linear relationship and vary from patient to patient within a specific diagnostic 
category such as pSS, recommendation of a validated symptom questionnaire is critical, 
pivoted against activity and damage scoring of clinical disease [52]. The ocular 
symptomatology can lead to high levels of anxiety, depression and fatigue [53, 54].  Non-
scripted, non-standardised verbal interviews are discouraged and questionnaires validated 
for discriminative ability, reproducibility and repeatability are recommended. The ocular 
surface disease index© (OSDI, Allergan Inc) score measuring domains of experience, 
performance and discomfort related quality of life spread over 12 questions provides a score 
out of 100 gauging severity of dry eye symptoms. It is the most widely used and accepted. An 
alternative, if time is limited, is the shorter five item Dry Eye Questionnaire (DEQ-5) covering 
discomfort, dryness and watery eye domains [55]. Continuous visual analogue scales for daily 
monitoring such as the Symptoms Analysis in Dry Eye (SANDE), tested against the OSDI, 
showed a significant correlation and negligible score differences compared with those from 
the OSDI, [56] making it a short, quick and reliable measure for dry eye symptom. A DEQ-5 ≥ 
7 or OSDI ≥ 13, together with a positive response to the TFOS DEWS II triage question “Do you 
have any moth dryness and swollen glands?” should raise the suspicion of Sjögren’s Syndrome 
[51].  
Objective homeostatic markers for the measurement of clinical aspects of disease includes a 
range of tests summarised in Table 2. Tear film osmolarity provides an objective, automated 
means of sampling the tear film just above the lower lid that can easily be carried out in non-
specialist clinics. A positive result is considered to be ≥308mOsm/L or an interocular 
difference of >8mOsm/L. Due to the variability between patients, longitudinal sampling is 
required to map progression of disease or response to therapy. The test could be useful in a 
clinical trial setting for measuring the impact of innovative technologies for the treatment of 
pSS on the ocular aspects of the disease. 
  
 
In day to day clinical practice, TFOS DEWS II recommends non-invasive break-up time and 
ocular surface staining for the diagnosis and monitoring of dry eye disease. Non-invasive 
break-up time without the use of fluorescein is preferred but invasive (fluorescein) break-up 
time may be substituted if non-invasive imaging is not available. In this situation, fluorescein 
is instilled in the outer canthus and slit-lamp viewing should take place 1-3 minutes after 
instillation with a positive finding recorded as <10 seconds. Quantification of ocular surface 
staining remains the mainstay for dry eye assessment. The two most commonly used staining 
patterns for pSS are the van Bijsterveld schema [57] and the Ocular Staining Score (OSS) [58] 
(figure 2). In the van Bijsterveld schema the intensity of lissamine green (a dye that stains 
devitalised epithelial cells and has replaced Rose Bengal) is scored in the two exposed 
conjunctival zones and cornea are scored between 0-3, giving a maximum score of 9. The 
Ocular Staining Score is more sensitive technique. The use of lissamine green for conjunctival 
scoring for nasal and temporal regions (grades 0-3) giving a maximum conjunctival score of 6 
per eye and fluorescein (a dye that stains de-epithelialised areas) for corneal scoring 
delivering a score of 0-3 with added weighting for confluent and pupillary area staining and 
the presence of filaments, giving a maximum corneal score of 6 per eye. The resultant 
composite conjunctival and corneal score confirms clinical features compatible with dry eye 
with a score >3, but the threshold of 5 has been retained for the ACR/EULAR diagnosis criteria 
[40]. Due to the non-linear relationship of the symptoms and signs, the OSDI and OSS used 
together provide a tailored monitoring ocular tool-set to enable effective counselling of pSS 
with improvement in either score motivating the patient to continue with self-help 
interventions such as modification of local environment and diet, together with warm 
compresses, lid hygiene and the use of regular and frequent lubricants. Schirmer's test uses 
graduated filter paper strips inserted into the eye for 5 minutes to measure the production of tears. 
The paper is then removed, and the amount of moisture is measured: the test is considered as 
positive for pSS diagnosis if moisture is ≤ 5 mm in 5 minutes. Despite a relatively poor sensitivity, 
the Schirmer’s test is still also use in clinical practice and remained in the most recent 
ACR/EULAR diagnosis criteria [40]. Effectively, easily done by any physician, without requiring 
an ophthalmologist expertise, it represents a practical screening alternative to more complex 
test. However, it cannot assess the severity of ocular surface involvement. 
Evidence based experience in pSS is extremely limited since clinical trials focusing on dry eye 
usually recruit patients with various underlying disease that do not allow us to generalise their 
conclusion to pSS patients. By contrast in pSS dedicated trials, evaluation of dry eye is usually 
limited and generally there is no record of ocular symptoms and signs as an outcome 
measure, or outcome measures with poor sensitivity (such as the Schirmer’s test) are used 
that do not generate robust efficacy data. In addition, the generic evaluation of dryness 
usually does not clearly differentiate between oral, ocular and eventually other dryness 
features. 
 
2.3. Fatigue and Pain  
The simplest way of measuring fatigue (or pain) is to use a 10 cm VAS or 0-10 Likert rating 
scale from ‘no fatigue (or pain)’ to ‘worst fatigue (or pain) imaginable’. Using fatigue as an 
exemplar this approach has been used in a number of Sjogren’s trials [8, 46, 59]. To date none 
of the larger studies have demonstrated a clear-cut effect on improving fatigue, although the 
TEARS study of Rituximab led to a modest 10-15% improvement in fatigue at 6 weeks. Another 
approach is to use a questionnaire comprising a series of questions addressing different 
components of fatigue. Some of these such as the FACIT-F scale [60] and the Fatigue Severity 
Scale [61] are ‘uni-dimensional i.e. they give a total score for fatigue whereas others such as 
the Multidimensional Fatigue Inventory (MFI) [62] or the Piper Fatigue Scale (PFS) [63] are 
‘multi-dimensional’ i.e. they have a number of domains or subscales that measure different 
aspects of fatigue such as physical or mental components of fatigue, fatigue severity, the 
effect of fatigue on daily activities or the emotional consequences of fatigue. In terms of their 
use in clinical trials in pSS they are typically used as a secondary outcome measure to validate 
the data from the VAS or Likert scale.  
The Profile of Fatigue and Discomfort (PROFAD) questionnaire [64] was specifically 
developed from interviews with pSS patients and by using the qualitative data from these to 
create and then refine an initially very broad questionnaire that captured key symptoms in 
patients with pSS. The key domains identified were, as expected, physical and mental fatigue, 
limb pain and also vascular features attributed to Raynaud’s syndrome. Both a short-form and 
brief version [65] of this questionnaire were developed. In parallel to the PROFAD, a Sicca 
Symptoms Inventory (SSI) using the same methodology in the same participant group was 
also developed as a measure of dryness symptoms [43] and offers an alternative to the OSDI 
described in the ocular indices section of this chapter. The brief form of the PROFAD-SSI, 
alongside the empiric measurement of dryness, fatigue, pain, and ‘global’ health in trials such 
as TRIPPS was in turn the progenitor of the EULAR Sjogren’s Syndrome Patient Reported Index 
(ESSPRI) now widely used to measure dryness, fatigue and pain in clinical trials and other 
studies in pSS [2]. The ESSPRI uses 0 to 10 numerical scales, one for the assessment of each 
of the 3 domains: dryness, fatigue and musculoskeletal pain (Figure 3). The weights of the 
domains are identical, and the mean of the scores of the 3 domains represents the final score. 
The ESSPRI has been shown to have an excellent reliability, but a lower sensitivity to 
change than ESSDAI [66]. As for ESSDAI, relevant thresholds have been determined with 
ESSPRI [14]. Thus, the patient satisfactory symptom state (PASS) has been defined as an 
ESSPRI<5 and MCII as an improvement of ESSPRI at least 1 point or 15%. 
 
 
2.4. Global and Health-Related Quality of Life Measures 
Quality of Life (QoL) is a broad concept generally described as a sense of well-being. It 
attempts to compare this across very different cultures and societies. The World Health 
Organization Quality of Life Questionnaire (WHOQOL) [67] has four principal domains namely; 
physical, psychological, social relationships and environment. Health-Related QoL (HRQoL) is 
a more limited concept where the focus is on how a disease affects an individual or a group. 
The Medical Outcomes Short-Form 36 item (SF-36) questionnaire is the most widely used 
HRQoL questionnaire. Multiple studies have shown impaired HRQoL levels in pSS patients as 
measured by the SF-36 or another widely used measure the EQ5D [25, 64, 68, 69]. Generally, 
these measures are insufficiently sensitive to change in short-duration clinical trials, but they 
have the benefit of facilitating health economic assessment and are therefore valuable 
secondary outcome measures to calculate quality assisted life years (QALY’s) as a marker of 
the economic benefit of novel therapies. 
 
3. Combination approaches  
Over the past 10 years or so various initiatives have clarified a number of outcome 
components for use in clinical trials in pSS. The ESSPRI is a simple tool to measure fatigue, 
pain and dryness symptoms. Combining the dryness component with objective measures of 
tear and saliva flow, along with histological evaluation of the salivary glands and with the 
potential inclusion of an imaging modality allows for a comprehensive evaluation of glandular 
function. The ESSDAI, described elsewhere in this chapter has been developed to measure 
systemic features of the disease. In the absence of an effective therapy for pSS, it has been 
challenging to assess sensitivity to change of these tools and to effectively develop a 
composite measure to facilitate trials evaluating different components of the disease in the 
same study.  
Extensive work has been conducted and major changes have occurred in the past 5 
years in the methodology of conducting clinical trials in pSS. Most recent and ongoing trials 
focused on patients with moderate to severe activity and used the ESSDAI (table 3), a systemic 
activity measure. With this new design, for the first time a randomised controlled trial 
reached its primary endpoint showing a significant improvement of the ESSDAI [23]. 
Nevertheless, we must emphasise that trials focusing on symptoms and those focusing on 
systemic activity should not be exclusive. In pSS patients, the lower quality of life is mainly 
driven by the patient-reported outcomes such as sicca scores or ESSPRI than by the ESSDAI 
[25]. Also, in post-hoc analyses of the TEARS study, a combined index, the Sjogren’s syndrome 
Responder Index (SSRI) has been proposed [70]. It combines patient-assessed visual analogue 
scale scores for fatigue, oral dryness and ocular dryness with unstimulated whole salivary flow 
rate and ESR. The SSRI is based on responders in the TEARS study, even though the study drug 
itself was ineffective. An SSRI-30 response was defined as a ≥30% improvement in at least two 
of five outcome measures. The potential use of this index to evaluate the effect of targeted 
therapies other than rituximab needs to be further evaluated. Nevertheless, this data 
suggests that biologics might be effective on patient’s symptoms when considering patients 
with low or moderately active patients. Thus, although the study conclusions (and therefore 
the SSRI) are limited as a result, conceptually, this approach of analysis of positive clinical 
trials is needed to validate a composite measure in the future. Work is currently ongoing to 
develop a composite index that could include PROs, objective measures of dryness and 
systemic activity measures. 
 
Conclusion 
Overall, the evaluation of clinical manifestations in pSS focus on the 2 disease facets: 
patient symptoms (dryness, pain and fatigue), using specific and generic PROs, and systemic 
manifestations, principally using the ESSDAI. In the last 10 years, thanks to the huge 
methodological work and the emergence of new targeted therapies, major changes have 
occurred in the way of conducting clinical trials in pSS. And, in the most recent trials, systemic 
activity measures have been used as inclusion criteria and primary outcome, which led for the 
first time to encouraging results. Nevertheless, work is still ongoing to define response to 
treatment by combining PROs and measures of systemic activity 
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Table 1. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), 
Domain Activity level Description 
Constitutional 
 Exclusion of fever of infectious 
origin and voluntary weight loss 
No=0  Absence of the following symptoms 
Low=3 Mild or intermittent fever (37.5−38.5°C)/night sweats and/or involuntary weight loss of 5–10% of body 
weight 
Moderate=6  Severe fever (>38.5°C)/ night sweats and/or involuntary weight loss of>10% of body weigh 
Lymphadenopathy and lymphoma  
Exclusion of infection 
No=0 Absence of the following features 
Low=4 Lymphadenopathy≥1 cm in any nodal region or ≥2 cm in inguinal region 
Moderate=8 ≥2 cm in any nodal region or ≥3 cm in inguinal region and/or splenomegaly (clinically palpable or 
assessed by imaging) 
High=12 Current malignant B-cell proliferative disorder 
Glandular  
Exclusion of stone or infection 
No=0 Absence of glandular swelling 
Low=2 Small glandular swelling with enlarged parotid (≤3 cm), or limited submandibular (≤2 cm) or lachrymal 
swelling (≤1 cm) 
Moderate=4 Major glandular swelling with enlarged parotid (>3 cm), or important submandibular (>2 cm) or 
lachrymal swelling (>1 cm) 
Articular  
Exclusion of osteoarthritis 
No=0  Absence of currently active articular involvement 
Low=2 Arthralgias in hands, wrists, ankles and feet accompanied by morning stiffness (>30 min) 
Moderate=4 1–5 (of 28 total count) synovitis 
High=6 ≥6 (of 28 total count) synovitis 
Cutaneous  
Rate as ‘No activity’ stable long-
lasting features related to damage 
No=0 Absence of currently active cutaneous involvement 
Low=3 Erythema multiforma 
Moderate=6 Limited cutaneous Vasculitis (<18% of body surface area), including urticarial vasculitis, or purpura 
limited to feet and ankle, or subacute cutaneous lupus 
High=9 Diffuse cutaneous Vasculitis (>18% of body surface area) including urticarial vasculitis, or diffuse 
purpura, or ulcers related to vasculitis 
Pulmonary  
Rate as ‘No activity’ stable long-
lasting features related to damage, 
or respiratory involvement not 
related to the disease (tobacco use, 
etc) 
No=0 Absence of currently active pulmonary involvement 
Low=5 Persistent cough due to bronchial involvement with no radiographic abnormalities on radiography Or 
radiological or high resolution computed tomography evidence of interstitial lung disease with: no 
breathlessness and normal lung function test 
Moderate=10 Moderately active pulmonary involvement, such as interstitial lung disease shown by high resolution 
computed tomography with shortness of breath on exercise (New York Heart Association: NHYA II) or 
abnormal lung function tests restricted to: 70% >DLCO ≥40% or 80% >Forced vital capacity ≥60% 
High=15 Highly active pulmonary involvement, such as interstitial lung disease shown by high resolution 
computed tomography with shortness of breath at rest (NHYA III, IV) or with abnormal lung function 
tests: DLCO <40% or Forced vital capacity <60% 
Renal 
Rate as ‘No activity’ stable long-
lasting features related to damage 
and renal0involvement not0related 
to the disease. If biopsy has been 
performed, please rate activity 
based on histological features first 
No=0 Absence of currently active renal involvement with proteinuria <0.5 g/day, no haematuria, no 
leucocyturia, no acidosis or long-lasting stable proteinuria due to damage 
Low=5 Evidence of mild active renal involvement, limited to tubular acidosis without renal failure or 
glomerular involvement with proteinuria (between 0.5 and 1 g/day) and without haematuria or renal 
failure (glomerular filtration rate (GFR) ≥60 mL/min) 
Moderate=10 Moderately active renal involvement, such as tubular acidosis with renal failure (GFR <60 mL/min) or 
glomerular involvement with proteinuria between 1 and 1.5 g/day and without haematuria or renal 
failure (GFR ≥60 mL/min) or histological evidence of extra-membranous glomerulonephritis or 
important interstitial lymphoid infiltrate 
High=15 Highly active renal involvement, such as glomerular involvement with proteinuria >1.5 g/day, or 
haematuria or renal failure (GFR <60 mL/min), or histological evidence of proliferative 
glomerulonephritis or cryoglobulinemia related renal involvement 
Muscular  
Exclusion of weakness due to 
corticosteroids 
No=0  Absence of currently active muscular involvement 
Low=6 Mild active myositis shown by abnormal Electromyogram, Magnetic Resonnance Imaging (MRI)* or 
biopsy with no weakness and creatine kinase (N≤CK≤2N) 
Moderate=12 Moderately active myositis proven by abnormal Electromyogram, MRI* or biopsy with weakness 
(maximal deficit of 4/5), or elevated creatine kinase (2N<CK≤4N), 
High=18 Highly active myositis shown by abnormal Electromyogram, MRI* or biopsy with weakness (deficit ≤3/5) 
or elevated creatine kinase (>4N) 
Peripheral nervous system (PNS) 
Rate as ‘No activity’ stable long-
lasting features related to damage 
or PNS involvement not related to 
the disease 
No=0 Absence of currently active PNS involvement 
Low=5 Mild active PNS involvement, such as pure sensory axonal polyneuropathy shown by NCS or trigeminal 
(V) neuralgia, or proven small fiber neuropathy 
Moderate=10 Moderately active PNS involvement shown by NCS, such as axonal sensory–motor neuropathy with 
maximal motor deficit of 4/5, pure sensory neuropathy with presence of cryoglobulinemic vasculitis, 
ganglionopathy with symptoms restricted to mild/moderate ataxia, inflammatory demyelinating 
polyneuropathy (CIDP) with mild functional impairment (maximal motor deficit of 4/5 or mild ataxia) Or 
cranial nerve involvement of peripheral origin (except trigeminal (V) neuralgia 
High=15 Highly active PNS involvement shown by NCS, such as axonal sensory–motor neuropathy with motor 
deficit ≤3/5, peripheral nerve involvement due to vasculitis (mononeuritis multiplex, etc), severe ataxia 
due to ganglionopathy, inflammatory demyelinating polyneuropathy (CIDP) with severe functional 
impairment: motor deficit ≤3/5 or severe ataxia 
Central nervous system (CNS) No=0  Absence of currently active CNS involvement 
Rate as ‘No activity’ stable long-
lasting features related to damage 
or CNS involvement not related to 
the disease 
Moderate=10 Moderately active CNS features, such as cranial nerve involvement of central origin, optic neuritis or 
multiple sclerosis-like syndrome with symptoms restricted to pure sensory impairment or proven 
cognitive impairment 
High=15 Highly active CNS features, such as cerebral vasculitis with cerebrovascular accident or transient 
ischaemic attack, seizures, transverse myelitis, lymphocytic meningitis, multiple sclerosis-like syndrome 
with motor deficit 
Haematological  
For anaemia, neutropenia, and 
thrombopenia. Only auto-immune 
cytopenia must be considered  
Exclusion of vitamin or iron 
deficiency, drug-induced cytopenia 
No=0 Absence of autoimmune cytopenia 
Low=2 Cytopenia of autoimmune origin with neutropenia (1000<neutrophils<1500/mm3), and/or anaemia 
(10<haemoglobin<12 g/dL), and/or thrombocytopenia (100 000<platelets<150 000/mm3) Or 
lymphopenia (500<lymphocytes<1000/mm3) 
Moderate=4 Cytopenia of autoimmune origin with neutropenia (500≤ neutrophils ≤1000/mm3), and/or anaemia (8≤ 
haemoglobin ≤10 g/dL), and/or thrombocytopenia (50 000 ≤ platelets ≤100 000/mm3) Or lymphopenia 
(≤500/mm3) 
High=6 Cytopenia of autoimmune origin with neutropenia (neutrophils<500/ mm3), and/or or anaemia 
(haemoglobin<8 g/dL) and/or thrombocytopenia (platelets<50 000/mm3) 
Biological No=0 Absence of any of the following biological feature 
Low=1 Clonal component and/or hypocomplementemia (low C4 or C3 or CH50) and/or 
hypergammaglobulinemia or high IgG level between 16 and 20 g/L 
Moderate=2 Presence of cryoglobulinemia and/ or hypergammaglobulinemia or high IgG level >20 g/L, and/or recent 




Table 2: Tests for grading clinical features of dry eye disease in Sjögren’s Syndrome 
Parameter Test 
Tear film instability Invasive and non-invasive tear film break-up time 
Thermography 
Tear film volume Meniscometry 
Phenol-red test 
Schirmer’s test 




Ocular Surface Damage Ocular surface staining 
Conjunctival impression cytology 
Lid parallel conjunctival folds 
In vivo confocal microscopy 
Corneal sensitivity 
Ocular Surface Inflammation Redness  
Tear cytokine levels 
Surface markers using impression cytology 
In vivo confocal microscopy 
Meibomian gland dysfunction Interferometry 
Meibography 
In vivo confocal microscopy through the lids 
 
  
Table 3. Main results of randomized controlled studies of biologicals in pSS 
Reference Treatment N Primary endpoint 
Significant difference for primary 
endpoint 
(Sankar et al. 
2004)[9] 
Etanercept 14 
≥20% improvement from baseline for 2 of 3 domains: 
subjective or objective measures of dry mouth and dry 
eyes, and IgG level or ESR 
No 




At week 10 
≥30% improvement in 2 of 3 VASs measuring joint 
pain, fatigue, and the most disturbing dryness. 
No 
No differences for secondary 
outcomes 
(Dass et al. 2008)[71] Rituximab 17 
At week 24 
20% reduction in VAS fatigue score 
Yes 
(Meijer et al. 
2010)[44] 
Rituximab 30 
At weeks 5, 12, 24, and 48 
Improvement in the stimulated whole saliva flow rate 
Yes 
Significant improvement at weeks 
5 and 12 
(Devauchelle-Pensec 
et al. 2014)[46] 
TEARS 
Rituximab 122 
At week 24 
30-mm improvement in 2 of 4 VAS 
No 
but efficacy at week 6 and on 
secondary endpoints (mainly 
biological features) 




At 48 weeks 
30% improvement in VAS fatigue or oral dryness score 
No efficacy on primary and 
secondary enpoints 






At 12 weeks 
Change in ESSDAI 
Yes 
Significant ESSDAI improvement  
VAS: visual analogic Scale  
 
  
Figure 1 Legend:  Patient-reported outcomes and disease activity in ocular disease.  
Symptoms and signs frequently do not correlate. Quantification of dry eye disease is based upon TFOS DEWS II recommendations include patient 
markers using OSDI or DEQ-5 patient outcome instruments together with homeostatic markers of disease activity using non-invasive break-up 
time without fluorescein or with *fluorescein (if non-invasive technology is not available) after osmolarity measurement, followed by ocular 
surface staining with fluorescein and lissamine green. Symptoms excess of clinical signs may indicate neuropathic pain. (Abbreviations: TFOS 
DEWS II, Tear Film and Ocular Surface Society Dry Eye Workshop; DEQ-5, five-item dry eye questionnaire; OSDI©, ocular surface disease index)  
 
 
Figure 2. Comparison of the van Bijsterveld scoring method and the OSS (Ocular Staining Score). 
The van Bijsterveld score has a maximum of 9 points per eye and is considered positive if ≥4 in at least one eye. The OSS score has a maximum of 12 points per eye and is 




Figure 3 Legend: the the EULAR SS Patient Reported Index (ESSPRI) 
The ESSPRI uses 0 to 10 numerical scales, one for the assessment of each of the 3 domains: dryness, fatigue and musculoskeletal pain. The final 
score is the mean of the scores of the 3 domains represents and range from 0 to 10. 
 
 
